Types of Variation Filing in USA for Pharma: PAS, CBE-30, CBE-0 & Annual Report | Pharmashare Types of Variation Filing in USA for Pharma: PAS, CBE-30, CBE-0 & Annual Report Explained Last Updated: April 2026 | For: Regulatory Affairs, CMC, QA Professionals If you work in Regulatory Affairs for US FDA submissions, you face this … Read more
FDA 483 Observations Related to Inadequate Investigations in Pharmaceutical Manufacturing FDA Form 483 Observations Related to Inadequate Investigations in Pharmaceutical Manufacturing In the pharmaceutical industry, investigations are a critical component of the Quality Management System (QMS). Whether dealing with deviations, out-of-specification (OOS) results, customer complaints, environmental monitoring excursions, or product quality defects, a thorough and … Read more
FDA 483 Observations on CAPA & CAPA Effectiveness 2026 | Pharma Compliance Guide FDA 483 Observations on CAPA & CAPA Effectiveness: Why 42% of Warning Letters Quote This Updated: April 21, 2026 | Category: QA & Compliance | Reading Time: 9 min “Corrective and Preventive Action procedures are not adequate.” If you’ve seen a USFDA … Read more
CAPA and CAPA Effectiveness in Pharmaceutical Industry CAPA and CAPA Effectiveness in the Pharmaceutical Industry “CAPA Process in Pharmaceutical Quality Management System” Corrective and Preventive Action (CAPA) is one of the most critical elements of a Pharmaceutical Quality System (PQS). Regulatory agencies worldwide, including the FDA, EMA, MHRA, and WHO, expect pharmaceutical manufacturers to establish … Read more
Empty Pockets in Pharmaceutical Blister Packaging: Causes and Troubleshooting Empty Pockets in Pharmaceutical Blister Packaging: Causes, Impact, and Troubleshooting Blister packaging is one of the most widely used packaging formats in the pharmaceutical industry due to its ability to provide product protection, tamper evidence, and patient convenience. However, one of the common challenges encountered during … Read more
USFDA Inspection Systems in Pharma 2026 | 6 Systems + 483 Survival Guide USFDA Inspection Systems in Pharma: 6 Systems FDA Checks First + 2026 Survival Guide Updated: April 19, 2026 | Category: Regulatory Compliance | Reading Time: 10 min USFDA inspection is not an audit. Audit = you control timing. Inspection = FDA controls … Read more
FMEA Application in Pharma | ICH Q9 R1 Risk Management Guide + Template 2026 Application of FMEA Tool in Pharma Risk Management: Complete ICH Q9 R1 Guide 2026 Published: April 19, 2026 | Category: Quality Risk Management | Reading Time: 8 min Failure Mode and Effects Analysis = FMEA. It’s the first QRM tool USFDA … Read more
Risk Management in Pharma: ICH Q9 R1 Guide + 7 QRM Tools 2026 Quality Risk Management QRM is no longer optional in pharma. ICH Q9 R1 makes it mandatory across product lifecycle – from development to commercial manufacturing. But 80% of QA teams still do risk assessment as “copy-paste” exercise. Result: USFDA 483 for “Risk … Read more
ANDA Approval Process in USFDA: Complete Guide for Generic Drug Approval 2026 Want to launch a generic drug in USA? You need ANDA – Abbreviated New Drug Application approval from USFDA. Unlike NDA for innovators, ANDA proves your generic is same as Reference Listed Drug RLD in safety + efficacy. This guide covers ANDA vs … Read more
Vendor Management System (VMS) in Pharma: Complete GMP Compliance Guide 2026 In pharma, your product quality is only as good as your worst vendor. USFDA 483s and WHO audits fail companies not for their own mistakes, but for poor vendor control. A strong Vendor Management System VMS ensures every RM, PM, and service vendor meets … Read more
